Impact of Target Lesion and Nontarget Lesion Cardiac Events on 5-Year Clinical Outcomes After Sirolimus-Eluting or Bare-Metal Stenting

JACC: Cardiovascular Interventions

Volumn 2, Issue 6, 2009, Pages 498-503

  Chacko, Riya ^a   Mulhearn, Meredith ^a   Novack, Victor ^b   Novack, Lena ^b   Mauri, Laura ^b,c   Cohen, Sidney A ^d,e   Moses, Jeffrey ^f   Leon, Martin B ^f   Cutlip, Donald E ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f Howard Hughes Medical Institute   (United States)

Author keywords

atherosclerosis; restenosis; stent

Indexed keywords

RAPAMYCIN;

ADULT; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 66949174059     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.03.013     Document Type: Article

References (17)

1. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
3. Fajadet J., Wijns W., Laarman G.J., et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 (2006) 798-806
4. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
5. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
6. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
7. Harrington R.A., Hasselblad V., and Califf R.M. Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?. J Am Coll Cardiol 51 (2008) 33-36
8. Cutlip D.E., Chhabra A.G., Baim D.S., et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 110 (2004) 1226-1230
9. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
10. Hofma S.H., van der Giessen W.J., van Dalen B.M., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
11. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 116 (2007) 2634-2653
12. Marzocchi A., Saia F., Piovaccari G., et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 115 (2007) 3181-3188
13. Morice M.C., Serruys P.W., Barragan P., et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 50 (2007) 1299-1304
14. Schampaert E., Moses J.W., Schofer J., et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 98 (2006) 36-41
15. Glaser R., Selzer F., Faxon D.P., et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 111 (2005) 143-149
16. Jimenez-Quevedo P., Sabate M., Angiolillo D.J., et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 28 (2007) 1946-1952
17. Ambrose J.A. In search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention?. J Am Coll Cardiol 51 (2008) 1539-1542